Direct answer:The Minodir product receives a FDA listing correction mail and cannot be selected between “modify” and “release”. Changed to Unapproved Drug Other merely corrects the declaration category and does not qualify for sales; The cessation of listing does not mean that historical issues are automatically eliminated. The listing basis, the accuracy of data and the actual distribution status should be verified separately.
I. An anonymous consultation: Why is the client tangled with modifications or write-offs?
The most recent consultation concerned raw products from Minodil. The FDA mail provided by the business indicated that the listing of SPL was incorrect, that Minodil did not have a monograph to use for the declaration, and that, based on the formula presented, the category should be Unapproved Drug Other. The enterprise then proposed: “Is it a reclassification or a direct cancellation of the product?”
This is a question that needs to be broken down: on the one hand, the authenticity and accuracy of the data already submitted, and on the other, the basis for the legitimate entry of products into the United States market. In conjunction with this anonymous consultation, the relationship between the listing basis, the listing correction and the cessation of distribution is described below.
ii. Is Minodil an OTC that can be listed under the OTC Monograph?
This cannot be inferred. The identity of the non-prescription drug is different from the applicability of OTC Monochorph. The FDA public law enforcement documents point out to Minodil raw products as new medicines that require valid approval of applications to support listing, and cannot choose a monograph path based solely on “unprescripted” or “many of the same kind in the market”.
The formulation, concentration, formulation type, route of delivery, use and manufacturing arrangements are checked. The designation of products as “capricorns” or “continuing care” is not a substitute for the classification and listing of products by composition and actual claims to be medicines. See common boundaries.FDA Unapproved Drugs and NDC Guide。
III. Changed to Unapproved Drug Other, is FDA allowed to continue sales?
No.Marketing categories are used to describe declaration records and do not create an otherwise non-existent listing approval. The FDA’s request to correct the error category to Unapproved Drug Other does not imply that it has confirmed that the product can be legally sold.
| Matters | Questions addressed | It's not a presumption. |
|---|---|---|
| Correcting Category | Declaration of data consistent with actual state of control | Obtaining a listing permit or exempting from other obligations |
| NDC/Drug Listing Accept or Public Show | Submission of records, product identification and database information | FDA has been certified safe and effective or approved product |
| Legal grounds for listing | Whether the specific product is subject to an appropriate authorization and the corresponding conditions are met | As long as the ingredient is similar to another product, it's covered by its approval. |
Thus, the words “reclassified” could still be identified and the words “may continue to sell to the United States” could not be equated. The NDC Directory of the FDA itself also contains data on approved and unauthorised medicines, and explicitly admits them without approval.
Four. Can't the ANDA be filled out if it's not your own?
The point of judgment is...Whether the approval really covers specific products and related arrangements to be soldNot just to see who gets the number. Legitimate licensed drug tagging or distribution relationships should have verifiable product, manufacturing and supply chain bases; Can't copy the unconnected ANDA number to its own SPL.
A single check of a number or a general delegation of authority is not sufficient to prove that the product is covered. The verification should be carried out in conjunction with the authorization of the holder, the corresponding product, the specified agent type, the actual site of production, the label and the actual supply relationship; The same conclusion cannot be shared for different concentrations, formulations or complex products simply because they all contain Minodil.
If it is not possible to explain the relationship between the approved number and the product, the basis should be identified before the listing corrections or withdrawal arrangements are discussed. ViewableEvaluation of drug classification and listing routesCode requests or listings should not be used as clearance coverage reviews.
V. How should we distinguish between modification and cessation of listing?
| Actual situation | Matters to be verified separately | Predictable misunderstandings |
|---|---|---|
| To correct error records | Original SPL, FDA indicates problem and real product state | Change of one field to resolve all compliance issues |
| Decision to stop commercial distribution in the United States | Actual sales, channel inventories, final batches and application of termination updates | Delete the account or fill out the day date at will |
| Considered to have valid approval coverage | Approval of products and manufacturing, labelling, supply chain information | Just verbally claiming that the factory has an ANDA will keep the original report. |
The two types of action may be involved at the same time and cannot be simply two-way. The closure of a listing cannot be considered to automatically erase historical issues. FDA has stated in its public case that despite the cessation of relevant listings, uncorrected data issues remain recorded in compliance cases to prevent re-listing; This means that the “deactivated record” should be evaluated separately from the “correction problem” and that it cannot be assumed on a case-by-case basis that all enterprises will receive the same outcome.
VI. What information is most worthy of verification after receiving the FDA mail?
The following is a compilation of the information proposed by ALREG, which is not a fixed list of controls applicable to all notifications:
- Full mail, attachments to NDC and details of questions, actual date of receipt and response requests.
- Current and historical SPL, SET-ID, version, submission and acceptance.
- Formulations, concentrations of active ingredients, formulations, complete labels, birth, etc. are declared.
- Listed categories, ANDA/NDA and actual manufacturing and supply basis.
- Whether or not there has been an inventory of beaucords, whether they are still being distributed, the pipeline inventory and the batch validity period.
- (c) The respective information and authorizations of the subject, labeler, manufacturer and trustee.
This consultation mail requires accurate information and notification of the results of the correction within 30 days of receipt of the letter, and also suggests that the original NET-ID update be followed; These are the requirements in the mail and cannot be extrapolated to a uniform period of time for all FDA notifications. It should be based on actual communications and should not be referred to as official Warning Litter solely on the basis of the warning language in the mail.
The general listing update note for the FDA also requires that the original SET-ID be retained and that updates be processed through a new document version. Specific technical submissions, terminations of listings and regulatory lines of communication should be confirmed by cross-checking incoming letters with existing records.
VII. ACCOUNTABILITY OFFICIAL RESOURCES AND RECENT RESPONSE
- FDA|National Drug Code Directory: The range of the directory and the entry do not represent FDA approval.
- FDA|How to List a Drug: Listing information, version and update to the original SET-ID.
- FDA | 2025-01-29 Public Law Enforcement Documents for MND products: Quote the Unapproved New Drug Videoations section; The public case is not a consulting enterprise.
- FDA=2022-06-03 Public record of de-listing and uncorrected data: The boundaries used to explain that cessation does not automatically eliminate the original data problem.
Official sources last reviewed: 2026-11-11. Public enforcement cases illustrate the regulatory scope and are unrelated to the anonymized inquiry above.
viii. Have your Minodier products also encountered problems with listing or listing routes?
Whether not submitted or notified of FDA data verification, the product formulation label, the existing NDC/SPL and the summary of the listing basis may be prepared. All REG may proceed as agreed.Evaluation of drug classification and listing routesandDrug Listing and NDC Information Support; Whether other technical or individual regulatory responses are involved is first identified in terms of scope and division of labour.
Submission of Minoldier products to check path and listing information *
Relevant extension:Labeler Code, NDC and the basis for listing。 This verification does not commit FDA to accept, exempt from law enforcement or to allow the sale of products.
For the first time, the station has published, updated and collated information: 2026-11-11. Author: Mr. Otsun; Audit: Mr. Toto. The anonymous consultation is used only to illustrate the method of judgement, requiring confirmation to be made in conjunction with the facts of the product and the actual FDA document.